Activity of avibactam against Enterobacter cloacae producing an extended-spectrum class C β-lactamase enzyme

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 11, 2014, Pages 2942-2946

  Lahiri, Sushmita D ^a   Giacobbe, Robert A ^a   Johnstone, Michele R ^a   Alm, Richard A ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

AmpC; Cephalosporins; Resistance

Indexed keywords

AVIBACTAM; AVIBACTAM PLUS AZTREONAM; AVIBACTAM PLUS CEFTAROLINE; AVIBACTAM PLUS CEFTAZIDIME; AZTREONAM; BETA LACTAMASE AMPC; CEFEPIME; CEFPODOXIME; CEFTAROLINE FOSAMIL; CEFTAZIDIME; CEFTRIAXONE; UNCLASSIFIED DRUG; AMPC BETA-LACTAMASES; AZABICYCLO DERIVATIVE; BACTERIAL PROTEIN; BETA LACTAMASE; BETA LACTAMASE INHIBITOR;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENOME; BROTH DILUTION; CONTROLLED STUDY; ENTEROBACTER CLOACAE; ENZYME INHIBITION; ENZYME INHIBITOR INTERACTION; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; GENE EXPRESSION; GENOME ANALYSIS; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR MODEL; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ALIGNMENT; AMINO ACID SEQUENCE; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; ENZYMOLOGY; GENETICS; HUMAN; METABOLISM; MOLECULAR GENETICS; PROTEIN SECONDARY STRUCTURE; PROTEIN TERTIARY STRUCTURE;

AMINO ACID SEQUENCE; AZABICYCLO COMPOUNDS; BACTERIAL PROTEINS; BETA-LACTAMASE INHIBITORS; BETA-LACTAMASES; ENTEROBACTER CLOACAE; HUMANS; MOLECULAR SEQUENCE DATA; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY;

EID: 84928202650     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku237     Document Type: Article

References (9)

1. Wang X, Zhang F, Zhao C et al. In vitro activity of ceftazidime-avibactam and aztreonam-avibactam against 372 Gram-negative bacilli collected in 2011 and 2012 from 11 teaching hospitals in China. Antimicrob Agents Chemother 2014; 58: 1774-8.
2. Flamm RK, Stone GG, Sader HS et al. Avibactam reverts the ceftazidime MIC90 of European Gram-negative bacterial clinical isolates to the epidemiological cut-off value. J Chemother 2013; doi:10.1179/1973947813Y. 0000000145.
3. Levasseur P, Girard AM, Claudon M et al. In vitro antibacterial activity of the ceftazidime-avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 2012; 56: 1606-8.
4. Rodríguez-Martínez JM, Fernández-Echauri P, Fernández-Cuenca F et al. Genetic characterization of an extended-spectrum AmpC cephalosporinase with hydrolysing activity against fourth-generation cephalosporins in a clinical isolate of Enterobacter aerogenes selected in vivo. J Antimicrob Chemother 2012; 67: 64-8.
5. Nordmann P, Mammeri H. Extended-spectrum cephalosporinases: structure, detection and epidemiology. Future Microbiol 2007; 2: 297-307.
6. Porres-Osante N, Dupont H, Torres C et al. Avibactam activity against extended-spectrum AmpC b-lactamases. J Antimicrob Chemother 2014; 69: 1715-6.
7. Barnaud G, Labia R, Raskine L et al. Extension of resistance to cefepime and cefpirome associated to a six amino acid deletion in the H-10 helix of the cephalosporinase of an Enterobacter cloacae clinical isolate. FEMS Microbiol Lett 2001; 195: 185-90.
8. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-third Informational Supplement M100-S23. CLSI, Wayne, PA, USA, 2013.
9. Lahiri SD, Mangani S, Durand-Reville T et al. Structural insight into potent broad-spectrum inhibition with reversible recyclization mechanism: avibactam in complex with CTX-M-15 and Pseudomonas aeruginosa AmpC b-lactamases. Antimicrob Agents Chemother 2013; 57: 2496-505.